Deriving Drug Discovery Value from Large-Scale Genetic Bioresources: Proceedings of a Workshop (2016)
Chapter: Appendix A: Workshop Agenda
A
Workshop Agenda
Deriving Drug Discovery Value from Large-Scale Genetic Bioresources:
A Workshop
March 22, 2016
The Keck Center of the National Academies of Sciences, Engineering, and Medicine, Room 100
500 Fifth Street, NW
Washington, DC 20001
MEETING OBJECTIVES
- To address how progress can be made in discovering and validating promising targets and medicines for those targets by using data collected from large-scale genetic studies.
- To highlight current genomics-enabled drug discovery activities in industry, academia, and government and to share best practices for study design and data collection.
- To examine enabling partnerships and business models to facilitate the use of genetic data for drug discovery.
AGENDA
| 8:30–8:35 a.m. | Welcoming Remarks |
|
Geoffrey Ginsburg, Co-Chair of the Roundtable on Genomics and Precision Health |
|
|
Director, Duke Center for Applied Genomics and Precision Medicine; Professor of Medicine and of Pathology and Biomedical Engineering, Duke University Medical Center |
|
|
Russ B. Altman, Co-Chair of the Forum on Drug Discovery, Development, and Translation |
|
|
Professor of Bioengineering, Genetics, Medicine, and (by courtesy) Computer Science, Stanford University |
|
| 8:35–8:45 a.m. | Charge to Workshop Speakers and Participants |
|
Nadeem Sarwar, Workshop Chair |
|
|
President, Andover Product Creation Innovation Systems, Eisai Inc. |
SESSION I: DESIGNING COHORTS TO MAXIMIZE DISCOVERY CAPABILITIES
Objectives: To explore current gaps and opportunities in data collected in large cohort studies and what elements could enable a robust discovery toolbox.
|
Moderator: Geoff Ginsburg, Co-Chair of the Roundtable on Genomics and Precision Health; Director, Duke Center for Applied Genomics and Precision Medicine |
|
| 8:45–9:30 a.m. | Joe Vockley |
|
Chief Operating Officer and Chief Scientific Officer, Senior Vice President, Inova Translational Medicine Institute |
|
| Mark Daly | |
|
Co-Director, Program in Medical and Population Genetics, Broad Institute of the Massachusetts Institute of Technology and Harvard University |
|
| Aris Baras | |
|
Vice President, Co-Head, Regeneron Genetics Center, Regeneron Pharmaceuticals |
|
| 9:30–9:45 a.m. | Break |
| Kári Stefánsson | |
|
Chairman, Chief Executive Officer, and Founder, deCODE genetics |
|
| Richard Scheller | |
|
Chief Science Officer, 23andMe |
|
| 10:15–10:45 a.m. | Discussion with Speakers and Attendees |
SESSION II: CURRENT GENOME-ENABLED DISCOVERY ACTIVITIES RELATED TO BIORESOURCES
Objectives: To discuss current activities among stakeholder groups and innovative technologies, to identify gaps, and to explore opportunities for cross-sector engagement.
|
Moderator: John Carulli, Director, Precision Medicine, Biogen |
|
| 10:45 a.m.–12:00 p.m. | Russ Altman |
|
Professor of Bioengineering, Genetics, and Medicine, Stanford University |
|
| Lon Cardon | |
|
Senior Vice President of Alternative Discovery and Development, Head of Target Sciences, GlaxoSmithKline |
|
| Sohini Chowdhury | |
|
Senior Vice President, Research Partnerships, The Michael J. Fox Foundation |
|
| Sally John | |
|
Vice President, Computational Biology and Genomics, Biogen Idec |
|
| Tim Rolph | |
|
Vice-President, Program Value Enhancement, Pfizer Inc. |
|
| 12:00–12:45 p.m. | Discussion with Speakers and Attendees |
| 12:45–1:45 p.m. | WORKING LUNCH |
SESSION III: BUSINESS MODELS THAT SUPPORT BIORESOURCE DISCOVERY COLLABORATION
Objectives: To examine potential precompetitive business models and investments that can support discovery efforts and opportunities across stakeholder groups.
|
Moderator: Rajesh Ranganathan, former Vice President of Science and Regulatory Advocacy, PhRMA |
|
| 1:45–2:45 p.m. | Lynn Matrisian |
|
Vice President, Scientific & Medical Affairs, Pancreatic Cancer Action Network |
|
| Meg Ehm | |
|
Director, External Strategic Alliances, Genetics, GlaxoSmithKline |
|
| David Wholley | |
|
Accelerating Medicines Partnership and Foundation for the National Institutes of Health; Director, Research Partnerships, Foundation for the National Institutes of Health |
|
| Chas Bountra | |
|
Professor of Translational Medicine, Head of Structural Genomics Consortium, University of Oxford |
|
| 2:45–3:30 p.m. | Discussion with Speakers and Attendees |
| 3:30–3:45 p.m. | BREAK |
SESSION IV: WHERE DO WE GO FROM HERE?
Objectives: What are the short-term and long-term next steps for achieving effective collaboration among stakeholders? Are there incentives that should be explored? How can we maximize use of large-scale genetic bioresources to effectively translate research into drug discovery?
|
Moderator: Nadeem Sarwar, Workshop Chair; President, Andover Product Creation Innovation Systems, Eisai Inc. |
|
| 3:45–3:55 p.m. | Dan Tagle |
|
Associate Director for Special Initiatives, Office of the Director, National Center for Advancing Translational Sciences, National Institutes of Health |
|
| 3:55–4:25 p.m. | Panel Discussion |
| Russ Altman | |
| Chas Bountra | |
| Lon Cardon | |
| Mark Daly | |
| Richard Scheller | |
| 4:25–5:10 p.m. | Discussion with Speakers and Attendees |
| 5:10–5:25 p.m. | SESSION HIGHLIGHTS |
| John Carulli | |
| Geoff Ginsburg | |
| Rajesh Ranganathan | |
| 5:25–5:30 p.m. | CONCLUDING REMARKS |
| Nadeem Sarwar, Workshop Chair | |
|
President, Andover Product Creation Innovation Systems, Eisai Inc. |
|
| 5:30 p.m. | ADJOURN |
This page intentionally left blank.
